Placental Transmission of Human Parvovirus 4 in Newborns with Hydrops, Taiwan

Mao-Yuan Chen, Shiu-Ju Yang, and Chien-Ching Hung

In studying the epidemiology of parvovirus 4 (PARV4) in Taiwan, we detected DNA in plasma of 3 mothers and their newborns with hydrops. In 1 additional case, only the mother had PARV4 DNA. Our findings demonstrate that PARV4 can be transmitted through the placenta.

Transmission routes of human parvovirus 4 (PARV4), a recently discovered member of the Parvoviridae family (1), are not fully understood; studies have suggested that PARV4 is transmitted predominantly through the parenteral route (2,3). To study the epidemiology of PARV4 infection in Taiwan, we developed an in-house PARV4 immunoblot (4). During the process, we found regions of higher similarity in amino acid sequence between PARV4 and parvovirus B19 virus (B19V). They are LPGYNVGPNGEL (B19V VP1, aa 125–137) LPGYNVGPNGNL (PARV4 open reading frame [ORF] 2, aa 219–231) and YKYPYVLGQGDTL (B19V VP2, aa 157–170) YDYPYLGHQDNL (PARV4 ORF2, aa 499–512).

To exclude the possibility of antibody cross-reaction between PARV4 and B19V, we tested plasma samples sent to our laboratory for confirmation of B19V infection with PARV4 immunoblot. Unexpectedly, we detected PARV4 DNA in plasma from a mother and her newborn with hydrops. Therefore, we examined samples from 5 additional infants with hydrops.

The Study

During 2000–2009, our laboratory received blood samples from 6 infants with nonimmune idiopathic hydrops (Table 1). Paired mother–newborn plasma samples from 4 infants were available for this study; plasma from either the mother or newborn was missing in 2 instances. None of the blood samples from the newborns was cord blood. All infants (case-patients) had at least 2 of the following conditions: ascites, pleural effusion, pericardial effusion, skin edema, or polyhydramnios.

Antibodies to PARV4 and B19V were tested by immunoblots. DNA of PARV4 and B19V was detected by seminested and nested PCR, respectively. PARV4 immunoblot and PCR were performed according to the methods in our previous report (4). The B19V immunoblot and PCR are described in the online Technical Appendix (www.cdc.gov/EID/content/17/10/10-1841-Techapp.pdf). The 2 fragments of the PARV4 capsid protein, aa 272–630 and aa 604–914 of ORF2, were fused to bacterial small ubiquitin-like modifier (SUMO) protein (a member of a ubiquitin-like protein family) and used as antigens in immunoblot. They were named viral protein (VP) 2 and VP3. For B19V, the antigens were VP1-specific (VP1-S; VP1, aa 1–227) fused to thioredoxin and VP2N (N terminal of B19V VP2, aa 1–343) fused to SUMO. The control protein was ribosomal P2 protein fused to SUMO. Antibodies to ribosomal P2 protein were rarely detected, except in patients with systemic lupus erythematosus (5).

Four of the 5 mothers had immunoglobulin (Ig) M against PARV4 (Table 2). Two of the 4 also had IgG against PARV4 (Figure, A, E); the other 2 had weakly positive IgM without IgG (not shown). No newborn had IgM against PARV4. We detected IgM against B19V in only 1 mother (Figure, A), who also had IgM against PARV4. None of the newborns had IgM against B19V. Two mothers (Figure, B, E) and 2 newborns had IgG against VP2N but not VP1S. The immunoblot pattern of IgG against B19V was inconsistent with findings in a previous report (6).

Only the mother and newborn of case A had detectable B19V DNA (genotype 1). By contrast, PARV4 DNA (genotype 2) was found in plasma of all but 1 of the 6 case-patients. The newborn negative for PARV4 DNA received a whole-blood exchange before sampling.

Conclusions

The first serologic study (7) and a recent study (8), both conducted in northern Europe, supported the fact that PARV4 is primarily a blood-borne virus. PARV4 DNA was detected in blood donors (9,10), and detection rates were 2% and 3.95%, respectively. The PARV4 seropositivity rate is expected to be higher than the DNA detection rate in blood donors because of the possibility of past infection (2,11,12). However, the IgG seroprevalence in 199 blood donors in France was 0%; the same rate was found in the general population in the United Kingdom (13). A much lower PARV4 DNA detection rate in blood donors in France may explain the result. Inconsistent with the findings of extremely low seroprevalence in France and the United Kingdom, PARV4 DNA was detected in the liver (15% and 41%, respectively) and the heart (41%)
of non–HIV-infected patients in Germany (11) and Italy (14). PARV4 infection might be more widespread in some countries in Europe.

Contrary to the epidemiology of PARV4 in Europe, studies in Africa found different transmission routes and a higher seropositive rate in blood donors and the general population. In Ghana, 8.6% of infants had PARV4 viremia (15). In sub-Saharan Africa, 20%–37% of adults studied had antibodies to PARV4 (13). The groups studied in both reports did not have parenteral risk.

PARV4 can be transmitted through nonparenteral routes (13,15). Our study showed that placental transmission is one of them. PARV4 was unlikely to have been transmitted through a blood transfusion because of the low detection rate of PARV4 DNA in the blood donors. Because Taiwan has a high PARV4 seroprevalence rate (4), the concern is not realistic.

Maternal PARV4 infections were diagnosed by detection of PARV4 DNA in all 5 mothers; 4 of whom had IgM against PARV4. Using IgM against PARV4 as evidence of recent infection must be done cautiously because of persistent IgM against PARV4 (4). Two mothers had weak IgM but no IgG against PARV4. The possibility of nonspecific IgM binding is low because of PARV4 viremia. The IgM result may be negative if the 2 samples are tested by enzyme immunoassay. The 2 mothers might have defective humoral immunity against PARV4 because we had detected 4 non–HIV-infected patients who had persistent IgM against PARV4 but did not have (or had weakly positive) IgG against PARV4 over 9–35 months. In a mother without IgM against PARV4, the amount of IgM might rapidly decline or a relapse of viremia might occur. In our previous longitudinal study of blood with IgM against PARV4, we found PARV4 DNA transiently during

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Delivery</th>
<th>Gestational age, wk</th>
<th>Birthweight, g</th>
<th>Hydrops signs</th>
<th>Hemoglobin, g/dL</th>
<th>Transfusion†</th>
<th>Platelets, 10^3/μL</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>F</td>
<td>CS</td>
<td>35</td>
<td>2,846</td>
<td>Pericardial effusion, polyhydramnios</td>
<td>8.1</td>
<td>Yes</td>
<td>NA</td>
<td>Survived</td>
</tr>
<tr>
<td>B</td>
<td>M</td>
<td>Vaginal</td>
<td>40</td>
<td>2,468</td>
<td>Pleural effusion, skin edema</td>
<td>7.9</td>
<td>Yes</td>
<td>183</td>
<td>Survived</td>
</tr>
<tr>
<td>C</td>
<td>F</td>
<td>CS</td>
<td>32</td>
<td>3,070</td>
<td>Pleural effusion, skin edema</td>
<td>7.8</td>
<td>Yes</td>
<td>22</td>
<td>Died</td>
</tr>
<tr>
<td>D</td>
<td>M</td>
<td>CS</td>
<td>35</td>
<td>3,030</td>
<td>Ascites, pericardial effusion</td>
<td>4.1</td>
<td>Yes</td>
<td>6</td>
<td>Survived</td>
</tr>
<tr>
<td>E</td>
<td>M</td>
<td>Vaginal</td>
<td>27</td>
<td>1,450</td>
<td>Pleural effusion, skin edema</td>
<td>13</td>
<td>No</td>
<td>232</td>
<td>Survived</td>
</tr>
<tr>
<td>F</td>
<td>M</td>
<td>CS</td>
<td>32</td>
<td>2,634</td>
<td>Ascites, pleural effusion</td>
<td>12</td>
<td>No</td>
<td>76</td>
<td>Died</td>
</tr>
</tbody>
</table>

*CS, cesarean section; NA, not available.
†All transfusions were given after delivery. Blood samples were collected on the second (patients A–D) or third (E, F) day after delivery.

Table 2. Antibody to B19V and PARV4 and detection of viral DNA in mothers and newborns, Taiwan, 2000–2009*

<table>
<thead>
<tr>
<th>Case and patient</th>
<th>Antibody</th>
<th>DNA</th>
<th>Antibody</th>
<th>DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Mother</td>
<td>IgM+, IgG+; anti-VP1 and 2</td>
<td>+</td>
<td>IgM+, IgG+</td>
<td>+</td>
</tr>
<tr>
<td>Newborn</td>
<td>IgM−, IgG+; anti-VP1 and 2</td>
<td>+</td>
<td>IgM−, IgG+</td>
<td>+</td>
</tr>
<tr>
<td>B Mother</td>
<td>IgM−, IgG+ to VP2 only</td>
<td>–</td>
<td>IgM−, IgG+</td>
<td>+</td>
</tr>
<tr>
<td>Newborn</td>
<td>IgM−, IgG+ to VP2 only</td>
<td>–</td>
<td>IgM−, IgG+</td>
<td>+</td>
</tr>
<tr>
<td>C Mother</td>
<td>IgM−, IgG−</td>
<td>–</td>
<td>IgM weak +, IgG−</td>
<td>+</td>
</tr>
<tr>
<td>Newborn</td>
<td>IgM−, IgG−</td>
<td>–</td>
<td>IgM−, IgG−</td>
<td>–</td>
</tr>
<tr>
<td>D Mother</td>
<td>IgM−, IgG−</td>
<td>–</td>
<td>IgM weakly positive, IgG−</td>
<td>+</td>
</tr>
<tr>
<td>Newborn</td>
<td>IgM−, IgG−</td>
<td>–</td>
<td>IgM−, IgG−</td>
<td>+</td>
</tr>
<tr>
<td>E Mother</td>
<td>IgM weakly positive, IgG+, to VP2 only</td>
<td>–</td>
<td>IgM+, IgG+</td>
<td>+</td>
</tr>
<tr>
<td>F Newborn</td>
<td>IgM−, IgG+; to VP2 only</td>
<td>–</td>
<td>IgM−, IgG+</td>
<td>+</td>
</tr>
</tbody>
</table>

*B19V, parvovirus B19 virus; PARV4, parvovirus 4; Ig, immunoglobulin; +, positive; VP, viral protein; −, negative.
of PARV4 infection on fetal outcome. Infection during pregnancy are needed to clarify the effect.

Antibodies can cross-react with those of B19V VP2N. PARV4. Therefore, the best explanation is that PARV4 result was not seen in 47 blood samples without IgG against only one of which tested positive by IBL. The paradoxicalTwenty-four samples had IgG against VP2N but not VP1S, VP2N and VP1S were positive in our B19V immunoblot. On the contrary, 4 samples in this study had IgG against B19V VP1 but not VP2 in immunoblot (6). Six IgG against B19V VP1 but not VP2 in immunoblot (6).

In conclusion, PARV4 can be transmitted parenterally. Other transmission routes might exist and placently. Other transmission routes might exist and remain to be discovered. Prospective studies of PARV4 infection during pregnancy are needed to clarify the effect of PARV4 infection on fetal outcome.

This study was supported partly by Taiwan Centers for Disease Control (DOH96-DC-1009).

Dr Chen is a physician in the Department of Internal Medicine National Taiwan University Hospital, Taipei. His primary research interests are autoantibodies, HIV infection, parvovirus B19V infection, and PARV4 infection.

**References**


Address for correspondence: Mao-Yuan Chen, National Taiwan University Hospital–Internal Medicine, No.7 Chung Shan South Rd, Taipei 1000, Taiwan, Province of China; email: maoyuanchen@ntu.edu.tw
Placental Transmission of Human Parvovirus 4 in Newborns with Hydrops Fetalis, Taiwan

Technical Appendix

Blood Samples

Infants with nonimmune idiopathic hydrops fetalis are not routinely checked for parvovirus B19 infection. That is why only 6 cases were available for the present study. Other causes of hydrops had been excluded, such as genetic causes and cardiovascular abnormalities. None of the 6 mothers was an injection drug user.

Methods

B19 Recombinant Fusion Proteins

Two B19 proteins were made, viral protein VP1S (VP1-specific, VP1 aa 1–227) and VP2N (N-terminal of B19 VP2, aa 1–343). VP1S fragment was produced by PCR by using plasma B19 DNA from HIV-1–infected patient CH (1) as template. The primers used were VP1S sense 5′-CTCGAGATGAGTAAAGAAAGTGGCAA (nt 2444–2463, number according to Au isolate, Xho I restriction enzyme site at 5′), VP1S antisense 5′-GAATTCGCTTGGGTATTTTCTGAGGC (nt 3124–3104, EcoRI enzyme site at 5′), VP2N sense (nt 3125–3144) 5′-ATGACTTCAGTTAATTCTGC and VP2N antisense (nt 4159–4136) 5′-TTATTATCTGTGTCCAGTGCG. The cycling conditions were: 94oC for 2 min, followed by 35 cycles of 94oC for 30 sec, 55 oC for 30 seconds, 72 oC for 2 min, and a final extension of 7 min at 72 oC. VP1S PCR product was cloned by TA cloning kit (pCRII Invitrogen, Carlsbad, CA, USA). The cloned VP1S gene was cleaved out by restriction enzyme Eco RI and Xho I and then ligated to pThioHis A protein expressing vector (Invitrogen). The VP2N PCR product was ligated to pET SUMO vector (Invitrogen). The production and purification of recombinant fusion proteins were done according to manufacturer’s manuals.
**B19 Immunoblot**

The immunoblot method was the same as PARV4 immunoblot (2).

**B19 PCR**

DNA was extracted from 200 μL plasma by using High Pure Viral Nucleic Acid Kit (Roche, Mannheim, Germany). The final elution volume was 50 μl, and 5 μL was used in the reaction. B19 DNA was detected by nested PCR. The primers were P1f, P1r, n-P1f and n-P1r (3). The cycling conditions were: 94oC for 2 minute, followed by 35 cycles of 94oC for 30 sec, 55 oC for 30 sec, 72 oC for 30 sec, and a final extension of 2 min at 72 oC. The PCR products were purified by QIAquick PCR purification kit (QIAGEN) and sequenced by DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems).

**References**

